In late 2021, the omicron variant of SARS Coronavirus 2 (SARS-CoV-2) emerged and
replaced the previously dominant delta strain. Effectiveness of COVID-19 vaccines against …

The recently discovered SARS-CoV-2 variant Omicron (B. 1.1. 529) has rapidly become a
global public health issue. The substantial mutations in the spike protein in this new variant …

Background Currently, as the omicron variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) surges amid the coronavirus disease 2019 (COVID-19) …

BACKGROUND Immunization against SARS-CoV-2, the causative agent of COVID-19,
occurs via natural infection or vaccination. However, it is currently unknown how long …

Impaired response to COVID-19 vaccination is of particular concern in immunosuppressed
patients. To determine the best vaccination strategy for this vulnerable group we performed …

The emergence of different variants of SARS-CoV-2, including the Omicron (B. 1.1. 529)
variant in November 2021, has resulted in a continuous major health concern at a global …

Abstract Background and Purpose Waning immunity and the surge of SARS-CoV-2 variants
are responsible for breakthrough infections, ie, infections in fully vaccinated individuals …

The T-cell immune response is a major determinant of effective SARS-CoV-2 clearance.
Here, using the recently developed T-CoV bioinformatics pipeline (https://t-cov. hse. ru) we …

Despite the efficacy of antiviral drug repositioning, convalescent plasma (CP), and the
currently available vaccines against severe acute respiratory syndrome coronavirus 2 …

Patients with blood disorders who are immune suppressed are at increased risk for infection
with severe acute respiratory syndrome coronavirus 2. Sequelae of infection can include …